News | Stents Drug Eluting | May 29, 2018

OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES

Onyx 1-Month OCT study provides potential insights on DAPT duration in complex patients following stent implantation

OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES

May 29, 2018 – Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early vessel healing in its target patient population at one month following implantation of the Resolute Onyx drug-eluting stent (DES). The target population contained a high percentage of patients with complex coronary artery disease.

Presented at the EuroPCR Annual Meeting, May 22-25 in Paris, France, data from 15 patients – including 13 with acute coronary syndrome (ACS) – were evaluated using optical coherence tomography (OCT). OCT is a light-based intracoronary imaging modality that provides extremely high-quality images of the coronary wall, especially of the structures closest to the vessel lumen.

In the Onyx 1-Month OCT Study, patients implanted with the Resolute Onyx DES demonstrated an excellent early healing profile. Results showed an average of 88 percent of struts covered by neointimal formation (new cell growth over stent struts) and 92.3 percent of the total stented area showing complete strut coverage at one month, which includes the covered areas in between the struts.

“The signal of early healing is crucial for patients who may need to interrupt or discontinue dual antiplatelet therapy (DAPT) within a short period of time after receiving a stent,” said Elvin Kedhi, M.D., Ph.D., interventional cardiologist at Isala Hartcentrum in Zwolle, the Netherlands, one of the lead principal investigators of the Onyx 1-Month OCT Study. “These data help expand the growing body of clinical evidence that may support physicians in tailoring DAPT regimens for complex patients.”

The Onyx 1-Month OCT Study is the latest of several Medtronic-funded studies helping to generate additional clinical evidence to reinforce the understanding of healing and shorter DAPT regimens in complex patients. Last year, Medtronic announced the Onyx ONE Global Study, a randomized clinical trial that will compare one-month DAPT between two DES for the first time, which is currently enrolling. A similar study will launch in the U.S. and Japan later this calendar year and will help inform DAPT guidelines for newer-generation DES that currently favor bare-metal stents (BMS) for patients at an increased risk of bleeding who might require a shorter DAPT regimen.

In a separate analysis presented at the EuroPCR meeting, new data from the DAPT-STEMI trial in patients treated with the Resolute Integrity DES, showed excellent results in a prospective prespecified registry that evaluated all patients after six months of DAPT duration, prior to randomization. At six months, the patient-oriented composite primary endpoint (all-cause mortality, any myocardial infarction [MI], any revascularization, stroke and TIMI major bleeding [net NACCE]) occurred in 4.2 percent of patients, with low rates of target lesion revascularization (1.1 percent) and stent thrombosis (0.7 percent).

The Resolute Onyx DES with thinner struts features Core Wire Technology, an evolution of Continuous Sinusoid Technology (CST). CST is a unique Medtronic method of stent manufacturing, which involves forming a single strand of cobalt alloy wire into a sinusoidal wave to construct a stent. This enables greater deliverability and conformability to the vessel wall. With Core Wire Technology, a radiopaque inner core is incorporated within the cobalt alloy wire to enhance visibility for accurate stent placement. Core Wire Technology also enables thinner struts while maintaining structural strength.

The Resolute Onyx DES received CE (Conformité Européene) Mark in September 2014 and U.S. Food and Drug Administration (FDA) approval in April 2017.

For more information: www.medtronic.com

Related Content

Fragmin (dalteparin sodium) injection was cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Fragmin (dalteparin sodium) injection is now cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Technology | Antiplatelet and Anticoagulation Therapies | May 17, 2019
May 17, 2019 — The U.S.
PhaseBio Receives FDA Breakthrough Therapy Designation for Ticagrelor Reversal Agent
Technology | Antiplatelet and Anticoagulation Therapies | April 30, 2019
PhaseBio Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
People With Heart Disease at Risk When Pharmacies Close
News | Antiplatelet and Anticoagulation Therapies | April 24, 2019
April 24, 2019 — New research from the University of Illinois at Chicago shows that when pharmacies close, people sto
Study Finds Only Six Percent of Patients Taking Statins as Directed
News | Antiplatelet and Anticoagulation Therapies | April 18, 2019
A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second major adverse...
HonorHealth Research Institute Launches SynIVUS-DAPT Study
News | Antiplatelet and Anticoagulation Therapies | April 16, 2019
HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT Study. The clinical...
Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance
News | Antiplatelet and Anticoagulation Therapies | April 15, 2019
Despite national guidelines indicating statins can lower risk of heart attack and stroke, many patients who could...
Stopping DAPT After One Month Improved Outcomes in Stent Patients
News | Antiplatelet and Anticoagulation Therapies | March 25, 2019
Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but continued taking the...
Apixaban Effective in Specific Cohort of Non-Valvular Atrial Fibrillation Patients
News | Antiplatelet and Anticoagulation Therapies | March 19, 2019
The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis (apixaban...
Researchers Develop Reversible, Drug-Free Antiplatelet Therapy
News | Antiplatelet and Anticoagulation Therapies | February 19, 2019
A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer...
FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process
News | Antiplatelet and Anticoagulation Therapies | January 02, 2019
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval Supplement (PAS) for...
Overlay Init